Dimerix is pleased to provide shareholders with access to a recorded interview where CEO, Kathy Harrison discusses the recent dose optimisation ASX announcement for DMX-200.
MELBOURNE, Australia, 15 January 2018: Dimerix Limited (ASX: DXB), is pleased to provide shareholders with access to a recorded interview where CEO, Kathy Harrison discusses the recent dose optimisation ASX announcement for DMX-200 (see ASX release 8 January 2018).
CEO Kathy Harrison discusses Dimerix’s programs on Health Invest TV
Following the release of successful Phase 2a clinical trial data from our DMX-200 program in mid 2017, Dimerix commenced accelerated partnering discussions with potential partners in Europe and the US.
CEO Kathy Harrison was interviewed by Stuart Roberts, Senior Analyst with NDF Research in San Francisco during JP Morgan healthcare week on the potential for DMX-200. To view the video, please follow this link: http://dimerix.com/ceointerview/
In the video, the recent dose optimisation announcement for DMX-200 is also discussed. The completion of this work sets Dimerix up for Phase 2b trials and provides additional intellectual property around the program. To view the original announcement, click here.
Entitlement Offer Update
The Offer, which enables shareholders to subscribe for one new share for every two shares held in Dimerix is due to close this Friday at 7pm Australian Daylight Savings time.
Funds raised are important for the commercialisation of DMX-200 across the Chronic Kidney Disease areas of FSGS and Diabetic Nephropathy
Funds raised from the Entitlement Offer will be used to further the development plans for Dimerix's lead compound, DMX-200 for both FSGS and diabetic nephropathy and for the Company's various pre-clinical pipeline programs.
Importantly, the capital will be used to undertake the Company’s Phase 2b clinical trial for FSGS, and to complete the work required to file an Investigational New Drug application (IND) with the US Food and Drug Administration (FDA). It will also be used to consolidate the development planning for a potential diabetic nephropathy partnering opportunity.
Funding is key to progressing DMX-200 clinical programs towards being Phase 3-trial ready and in parallel, undertaking partnering discussions, which may present commercial inflection points.
About the Offer
The Entitlement Offer provides shareholders with the opportunity to subscribe for one (1) New Share for every two (2) Shares held at 7.00 pm (AEDT) on 11 December 2017 (settlement completed) at an issue price of $0.12 per New Share, which represents a discount of approximately 31% to the VWAP of Shares traded on ASX in the 15 days to 30 November 2017.
Eligible Shareholders may also apply for New Shares in excess of their Entitlement, although any application for Additional New Shares may be scaled back at the Company’s sole and absolute discretion.
Applications can be made via:
- BPAY (details are on noted on the mailed Entitlement and Acceptance Form); or
- By returning the personalised Entitlement and Acceptance Form together with a cheque to the Company’s Share Registry
If shareholders do not have access to their original mailed Entitlement and Acceptance form, they can access their Application Form electronically as follows:
- Registering on the Automic website.
- Once registered, click on the “Documents & Statements” option, then click “download” to access the form.
- To login, register the name of the shareholder, the HIN/SRN number and postcode (which must be the postcode recorded on the holding).
- Call the Company’s share registry, Automic on +61 8 9485 0821.
More information about the Offer
Details about the Offer can be viewed via this link:
http://dimerix.com/wp-content/uploads/1749285.pdf, which shareholders should read carefully before deciding whether to apply.
If you have any questions about the Entitlement Offer please contact Dimerix on +61 8 9388 8290 or your professional adviser.
Further information about the Entitlement Offer can be found on the Dimerix website, http://dimerix.com/rightsoffer/ which includes a section with frequently asked questions.
An audio interview with CEO Kathy Harrison discussing key questions relating to the Entitlement Offer can be accessed via http://dimerix.com/rightsinterview/.
Remember, to secure your allocation, funds must be received by the deadline of 7pm AEDT on Friday 19 January 2018.
